Detail akcie Diamyd Medical -B- online

Business Summary: Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.
Financial Summary: BRIEF: For the three months ended 30 November 2025, Diamyd Medical AB revenues increased from SEK25K to SEK244K. Net loss increased 35% to SEK48.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Profit/loss of sold shares or other secu decrease of 93% to SEK485K (income), External research and development costs increase of 17% to SEK30.5M (expense).